Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Batiraxcept - Aravive

X
Drug Profile

Batiraxcept - Aravive

Alternative Names: 3D-229; 3D-299; Aravive-S6; AVB 500; AVB S6 500; Axl fc fusion protein AVB-S6-500; Ruga-S6; S6-500c

Latest Information Update: 07 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Stanford University
  • Developer 3D Medicines; Aravive; Aravive Biologics; European Network of Gynaecological Oncological Trial Groups; Gynecologic Oncology Group
  • Class Antifibrotics; Antineoplastics; Antivirals; Immunoglobulin Fc fragments; Immunotherapies; Proteins; Recombinant fusion proteins
  • Mechanism of Action Axl receptor tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Cholangiocarcinoma; Fallopian tube cancer; IgA nephropathy; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Renal cell carcinoma; Renal fibrosis; Solid tumours; Unspecified; Urogenital cancer; Viral infections

Most Recent Events

  • 31 Jan 2024 Discontinued - Phase-III for Ovarian cancer (Combination therapy, Recurrent, Second-line therapy or greater) in Czech Republic (IV)
  • 31 Jan 2024 Discontinued - Phase-III for Ovarian cancer (Combination therapy, Recurrent, Second-line therapy or greater) in Italy (IV)
  • 12 Jan 2024 Discontinued - Phase-I for Acute myeloid leukaemia (In volunteers) in USA (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top